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Strengths and limitations of this study
 ► We invited pharmacists from 500 pharmacies across 
England to complete a survey.
 ► We mailed our survey with a single follow- up of non- 
responders (September 2018 to December 2018).
 ► Postcodes of pharmacies were linked with free-
ly available data on Index of Multiple Deprivation 
scores, which provides an estimate of the socioeco-
nomic deprivation of the practice population.
 ► The interactive application helps to visualise the 
data easily: https://portuni.maps.arcgis.com/apps/
webappviewer/index.html?id=a4ef6e48721649a-
da4eec362507245f6 or https://arcg.is/1jrevP
AbStrACt
Objectives The primary objective was to assess the 
accuracy (calibration and validation status) of digital 
blood pressure (BP) monitors used within community 
pharmacy in England and the secondary objectives were 
to assess the overall quality of the BP service by assessing 
service prevalence, service utilisation and other in- service 
considerations.
Design A cross- sectional survey.
Setting Primary- care retail- pharmacies.
Participants 500 pharmacies that contribute to 
government dispensing- data were invited by post to 
complete the survey. Private contractors were excluded.
Interventions We conducted a questionnaire survey with 
a follow- up (September 2018 to December 2018).
results 109 responses were received. 61% (n=66) 
of responding pharmacies provided a free BP check to 
their patients. 40 (61%) pharmacies used recommended 
validated clinical metres, 6 (9%) had failed validation and 
20 (30%) provided too little information to enable us to 
determine their monitor’s status.
Conclusions Responding pharmacies were able to 
provide useful BP monitoring services to their patients, 
though quality enhancements need to be implemented. 
Majority of pharmacies use validated BP monitors, 
however, there was a lack of range of cuff sizes, variation 
in replacement and calibration of monitors and apparent 
absence of such practice in a minority of pharmacies 
alongside variation in training standards. We noted 
higher frequency of BP screening in the most deprived 
postcodes.
We recommend in- service redesign and delivery 
improvements, and suggest professional bodies and 
researchers work together to create clearer frameworks 
for front- line practitioners, creating appropriate incentives 
to facilitate this service redesign.
Funders and policy setters should consider the value 
added to the National Health Service and other healthcare 
agencies of such screening by pharmacy providers both 
nationally and internationally. It has the potential to 
reduce complications of undiagnosed hypertension and 
the medicines burden that it creates. Future work should 
examine the impact of pharmacist- led BP screening on 
patients.
IntrODuCtIOn
Hypertension (high blood pressure (BP))
is the most important modifiable risk factor 
for cardiovascular, cerebrovascular and renal 
disease, and avoidable cause of premature 
morbidity and mortality.1–6
The Health Survey for England monitors 
trends in the nation's health, estimating the 
proportion of people in England who have 
specified health conditions, and the preva-
lence of risk factors and behaviours associated 
with these conditions.7 According to the 2016 
Survey, 28% of adults had hypertension, 10% 
had controlled hypertension and 12% had 
untreated hypertension. Thus, approximately 
7.9 million people were suffering from undi-
agnosed hypertension in 2016, who are at risk 
of heart attack or stroke, leading to hospital 
admission and reduced quality- of- life.
Public Health England (PHE) exists to 
protect and improve the nation's health and 
well- being, and reduce health inequalities. 
PHE is an operationally autonomous exec-
utive agency of the Department of Health.8 
The 2014 PHE figures reveal that diseases 
caused by high BP are estimated to cost over 
£2 billion annually.9 National Health Service 
(NHS) and social care spend of £850 million 
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could be avoided over 10 years by reducing the BP of the 
nation. If just 15% more people (1.185 million people), 
unaware they have high BP, are diagnosed, £120 million 
of NHS and social care spend could be avoided over 10 
years.9
Community pharmacists and their teams make an 
important contribution to the prevention, detection and 
management of high BP via routine public health promo-
tion, medicines optimisation services and through a wide 
range of targeted services and interventions specifically 
designed to detect, diagnose and manage hypertension 
as recommended by research, in national guidance from 
PHE and NHS England.10–13 Community pharmacy BP 
monitoring is readily available and recommended by 
Canadian hypertension guidelines.14
The digital BP monitors used within the services need 
to be of good quality (validated for clinical use15–18) and 
need regular maintenance (calibration) for accurate func-
tioning. This phenomenon has been well studied in physi-
cians’ offices,19–21 but less so in pharmacy settings.22–24
With increasing general practitioner (GP) shortages, 
pharmacy providers are more valued.25 26 They often have 
extended opening hours during evenings and weekends 
and are frequently located in comfortable and attractive 
retail spaces accessible within 20 min’ walk.27 Thus, they 
provide a less clinical space, more convenient for people 
with less access to healthcare.
Current standards for initial education and training 
on BP monitoring delivered to pharmacy undergrad-
uate students lack sufficient detail to be incorporated 
into a service specification. The independent pharmacist 
prescribers course28 specifies that students are able to use 
diagnostic aids relevant to the condition for which the 
pharmacist intends to prescribe.
Consequently, there is no certification or credentialing 
for providing a high- quality BP service via pharmacy in 
the UK. As there are no standard specifications integrated 
into the pharmacy contract, there is possibly quality vari-
ability across postcodes. Finally, there is no consensus 
on how or when referrals are made to medical doctors, 
though patients would be expected to be signposted to 
their GP.
This study seeks to understand the challenges faced 
by under pressure models of care in the Western world 
(growing patient demand, insufficient funding in primary 
care, changing patterns of demand, reduced access to GPs 
and addressing national health inequalities). This study 
aligns with the United Nations (UN)’s agenda for Sustain-
able Development Goals 3: to reduce by one- third prema-
ture mortality from cardiovascular disease by 2030.29 30
Objectives
The primary objective of this study was to assess the 
accuracy (calibration and validation status) of digital BP 
monitors used within community pharmacy in England 
and the secondary objectives were to assess the overall 
quality of the BP service. Secondary objectives were 
assessed by ascertaining prevalence of service provision, 
level of service utilisation, quality of service (how the 
monitor make and model was chosen, length of time 
in service, care and maintenance including calibra-
tion history, visual or physical checks before each use, 
instructions provided to patients before taking measure-
ments, available cuff sizes, relevant staff training) and 
estimated number of patients newly detected with 
hypertension. We also aimed to use this data to examine 
its association with geospatial location, dispensing data 
and Index of Multiple Deprivation (IMD) score which 
provides statistics on relative deprivation in small areas 
in England.31
MethODS
Participants and recruitment
We invited 500 pharmacies across England to complete a 
survey about their BP screening service.
Inclusion criteria: Community pharmacies that 
contribute to the NHS Business Services Authority (BSA) 
dispensing data (pharmacy- contractor reimbursement 
agency).
Exclusion criteria: Community pharmacies that are not 
NHS contractors, other settings that offer BP monitoring 
(eg, hospitals, GP surgeries, walk- in centres).
Addresses were taken from publicly available NHS 
BSA website (March 2018) to gain a nationally represen-
tative sample. We selected the first 500 pharmacies by 
Contractor Code (FA002 to FAQ67), ensuring they were 
nationally representative with respect to the number of 
prescription forms (invited sample mean 3633, SD 2053 
vs England population mean 3564, SD 2692) and number 
of prescription items dispensed (invited sample mean 
7366, SD 4296 vs England population mean 7132, SD 
5167). This permitted comparison with like for like busi-
nesses (approximately equal burden of work, similar team 
size and similar business complexity) across the country, 
therefore allowing fair comparison between pharmacies 
that provide the service and those that do not.
We mailed the survey with a single follow- up of non- 
responders from September 2018 to December 2018. 
Respondents were invited to provide self- reported 
answers. A prepaid self- addressed envelope was provided. 
The participants could include registered pharmacists or 
pharmacy support staff working in community pharmacy.
We sought and received favourable institutional ethical 
approval. No financial (or similar) benefits were offered 
to minimise biassed responses.32
Sample size
There are 11 619 community pharmacies in England 
in 2017 to 2018.33 Assuming confidence level of 95%, 
CI of 9.5%, relative SE of 9.69% a sample size of 106 is 
calculated. To achieve this, we invited 500 pharmacies as 
research and previous experience indicates a response 
range between 15% to 25% in similar studies.34–39
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Questionnaire
The questionnaire was composed of items relating to 
demographics, BP service provision and how it is deliv-
ered, blood pressure monitor details, associated training, 
visual or manual checks performed on monitors and 
instructions given to patients. The survey is detailed in 
online supplementary appendix A. We had previously 
iteratively tested the survey in a local pilot study.34
We piloted the questionnaire via six steps. Question-
naire validation (pretesting) was achieved by researchers 
critically appraising the scale in a research- team focus- 
group. This comprised two external practicing commu-
nity pharmacists, other academics with recent community 
and hospital practice experience and student researchers. 
This allowed for detection and deletion of ambiguous 
words, misinterpretation of questions, poor questions 
and sensitive questions. Amendments and improvements 
were made to the format, structure and content. To 
improve internal validity and reliability, the survey instru-
ment was piloted with another external community phar-
macist, and cognitive testing (read- aloud) was conducted. 
Further refinement was achieved with a research- team 
focus- group with contribution from experts at the 
research design service provided by the National Insti-
tute for Health Research. It took less than 10 minutes to 
complete the final survey.
Data analysis
Analyses were undertaken using SPSS.40 The results 
presented are descriptive, presented as proportions, 
correlational analysis and independent sample tests. 
Missing data are presented. For correlation coefficients, 
it is generally recognised that a reliability estimate needs 
to be above 0.70 and a validity estimate needs to be above 
0.60 to be at an acceptable level.41 All values above 0.6 
were examined. We used Levene’s test to assess statistical 
significance. Levene's test is an inferential statistic used 
to assess the equality of variances for a variable calculated 
for two groups (service providers vs non- providers). Some 
common statistical procedures assume that variances of 
the populations from which different samples are drawn 
are equal. Levene's test assesses this assumption.
Postcodes of pharmacies were linked with freely avail-
able data on IMD score, an estimate of the socioeco-
nomic deprivation of the practice population31 and NHS 
dispensing data.
We mapped our results using ArcGIS online and we 
created an interactive application to visualise the data 
easily: https:// portuni. maps. arcgis. com/ apps/ webap-
pviewer/ index. html? id= a4ef 6e48 7216 49ad a4ee c362 
507245f6. It is freely and publicly accessible.
We mapped our responses alongside the IMD 2015 
data (Ranks: every postcode has a rank from 1 which is 
the most deprived area up to 32 844 which is the least 
deprived area. Deciles are published alongside ranks 
to assess relative deprivation) to assess any relationship 
between deprivation and screening quality.
Ethics
We used the Strengthening the Reporting of Observa-
tional Studies in Epidemiology cross- sectional reporting 
guidelines.42
no patient and public involvement
We did not involve patients or the public in our work. 
This is likely to be done in the future.
reSultS
In total, 109 responses (21.8% response rate) were 
received, satisfying sample calculation needs. (74 
responses on first approach, 35 additional responses on 
follow- up, six closures and abatements, three spoiled/
defaced responses).
Sixty- one per cent (n=66) of responding pharmacies 
provided a free BP check to their patients.
Characteristics of service providers versus non- service 
providers on demographics are shown in table 1.
Service providers employed more full- time pharmacists 
and were less likely to be co- located in GP practices. We 
found of the 66 service providers, 57 worked full- time.
Table 2 demonstrates that pharmacists tended to lead 
the service delivery and tended to be more experienced. 
Employees involved in providing the BP check in the 
pharmacy included the whole team: 55 were pharmacists, 
two pharmacy technicians, seven dispensing assistants 
and one medicines counter assistant.
Pharmacies had provided the service for varying lengths 
of time: nine over 0 to 2 years, 12 over 3 to 6 years, 11 over 
7 to 9 years and 24 over 9 years (eight did not know, with 
two missing).
Service utilisation
All but one respondent provided monitoring solely within 
the pharmacy. One lent their BP monitor to patients for 
self- monitoring at home.
We enquired about monthly and annual screening 
figures because there may be distortions in some months 
when national or local health promotion campaigns 
are promoted (eg, ‘Know your Numbers!’, NHS Health 
Check, etc). In the last month, pharmacies reported 
providing BP screening as per table 3.
Over the last year, the people screened in each phar-
macy ranged from 10 to 2000 (mean 106.3, SD 295.2, 21 
missing), with 10 pharmacies serving 100 or more people. 
Only one respondent said 2000 patients screened, which 
could be an outlier but this pharmacy is associated with 
higher business volumes (prescription forms and items 
dispensed were 5613 and 10 144, respectively, IMD decile 
10- affluent).
When asked: ‘What is the number of patients newly 
detected with high BP (BP>140/90 mm Hg) in the last 
month?’ many could not give a clear answer, but estimates 
ranged from 0 to 25 with a high- frequency of ones and 
twos (mean 2.3, SD 4.0, 17 missing).
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Table 1 Response frequency
Variables
Respondent 
frequencies 
(Percentage) (n=109)
Service providers 
frequencies (Percentage) 
(n=66)
Levene's test for equality of
variances at 95%, where equal 
variances assumed
Role (two missing) (zero missing) F=0.706, p=0.403
  Pharmacist 90 (84%) 55 (83%)   
  Pharmacy technician 7 (7 %) 3 (4.5%)   
  Dispensing assistant 7 (7 %) 7 (11%)   
  Medicines counter assistant 3 (3 %) 1 (1.5%)   
Gender (three missing) (two missing) F=0.203, p=0.653
  Male 57 (54 %) 32 (50 %)   
  Female 48 (45 %) 32 (50 %)   
  Preferred not to say 1 (1 %)     
Years of registration experience (nine missing) (seven missing) F=0.730, p=0.395
  0–2 9 (8 %) 5 (8 %)   
  3–5 16 (15 %) 9 (15 %)   
  6–8 12 (11 %) 8 (14 %)   
  9–11 11 (10 %) 8 (14 %)   
  12–14 5 (5 %) 1 (2 %)   
  15–17 7 (7 %) 7 (12 %)   
  18–20 2 (2 %) 1 (2 %)   
  >20 years 38 (36 %) 20 (34 %)   
Employer type (two missing) (one missing) F=0.245, p=0.621
  National chain pharmacy 51 (48 %) 35 (54 %)   
  Independent pharmacy 56 (53 %) 30 (46 %)   
Work contract type (three missing) (one missing) F=8.904, p=0.004
  Full- time 90 (85 %) 57 (88 %)   
  Part- time 12 (11 %) 7 (11 %)   
  Locum 3 (3 %) 1 (2 %)   
  Other 1 (1 %) 0   
Location of community pharmacy (two missing) (one missing) F=0.471, p=0.494
  Urban 47 (44 %) 32 (49 %)   
  Suburban 47 (44 %) 26 (40 %)   
  Rural 13 (12 %) 7 (11 %)   
Co- located within GP practice (four missing) (two missing) F=4.766, p=0.031
  Yes 20 (19 %) 10 (16 %)   
  No 85 (81 %) 54 (84 %)   
Provide a BP monitoring service       
  Yes 66 (61 %)     
  No 43 (39 %)     
BP, blood pressure; GP, general practitioner.
Calibration, validation, cuff sizes, maintenance intervals
Overwhelmingly pharmacies (97%; n=61) reported using 
an automatic BP monitor during BP screening (where 
cuff inflation, deflation and BP determination are fully 
performed by the device automatically). Two respondents 
(3%) said they used a semi- automatic device (BP determi-
nation is performed automatically but cuff inflation and/
or deflation needs manual operation). None used manual 
sphygmomanometers (three missing). All measured BP 
at the upper arm.
We then explored the rationale behind choosing their 
particular monitor. Fifty- eight responses were received: 
25 (43%) respondents were given their monitor by head 
office (refers to any central office under the control of the 
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Table 4 Available cuff sizes
Available cuff sizes
Response 
frequency (n=50)
Small (18–22 cm) 7 (14%)
Medium (22–32 cm) 39 (78%)
Large (32–45 cm) 27 (54%)
Extra large (42–50 cm) 7 (14%)
Other ‘24 to 40 cm 9.4–15.7‘ 1 (2%)
Missing 16 (24%)
Table 2 Pharmacist and non- pharmacist respondents 
stratified by years of registration experience (small numbers 
may not add up to 100%)
Years of registration 
experience of service 
providers
Pharmacists 
(n=55)
Non- 
pharmacist 
(n=11)
0–2 5 (9%) 0
3–5 7 (13%) 2 (18%)
6–8 6 (11%) 2 (18%)
9–11 7 (13%) 1 (9%)
12–14 1 (2%) 0
15–17 7 (13%) 0
18–20 1 (2%) 0
>20 years 20 (36%) 0
Missing data 0 6 (55%)
Table 3 Number of patients screened in the last month
Number of patients screened Response frequency
1–5 25 (38%)
6–10 22 (34%)
11–15 8 (12%)
16–20 2 (3%)
20+ 8 (12%)
Total 65 (1 missing)
superintendent pharmacist, who takes legal responsibility 
for all business operations), 16 (28%) used a monitor 
that was convenient for them (often present in their 
own store for sale), seven (12%) had done some brand 
research, five (9%) participants identified their monitor 
as being ‘accredited’ and five (9%) were influenced by 
advertisement.
Further to this, 61 respondents provided a monitor’s 
brand, 50 provided a model number and 53 provided 
a batch number. We used the dablEducational Trust43 
and the British and Irish Hypertension Society (BIHS)44 
website to check their validation status.
Forty (61%) pharmacies used recommended validated 
clinical metres, 6 (9%) monitors had failed validation 
and 20 (30%) respondents provided too little informa-
tion to enable us to determine their monitor’s status. One 
monitor was validated but listed as discontinued by dabl 
and archived by BIHS, which makes its continued use 
questionable.
Regarding available cuff sizes, 50 responses were 
received, shown in table 4.
Though some branches had several cuff sizes in use, 23 
(46%) just had one cuff size.
Regarding length of monitor time in use, 43 valid 
responses were received. Dates ranged from 14 July 2005 
to 01 September 2018, thus covering anywhere from over 
13 years to 2 months. From this, we calculated length of 
time in service: 10 responders had their monitor in use 
between 0 to 1 year, 14 had their monitor in use between 
1 to 2 years, 12 had had their monitor in use between 2 
to 5 years, six had had their monitor in use between 5 to 
10 years and one had their monitor in use over 10 years.
Respondents replaced their BP monitor at different 
intervals; one person (2%) said they replaced 6 monthly, 
eight (13%) said annually, 26 (41%) said 2 yearly, 19 
(30%) said the metre had not been replaced and nine 
(14%) said other (three missing). We also asked if respon-
dents sent their monitor for calibration. Three (5%) sent 
it back to the manufacturer, 13 (20%) sent it back to head 
office and 44 (67%) did not send their monitor for cali-
bration (six missing). This demonstrates that community 
pharmacies to some extent replace the monitor rather 
than get it calibrated relying on monitors warranty status.
training
We explored issues around training to gain a better 
understanding of the level of knowledge, skill and educa-
tion of respondents regarding the blood pressure moni-
toring service.
Fifty- nine (92%) respondents said they received some 
form of training and five (8%) said they did not (two 
missing). Of those who received training, 32 (54%) indi-
cated only one form of training, while the others received 
multiple forms of training. The types of training are 
shown in table 5.
‘Other’ comments included training from internal and 
external providers (online and in- person), local clinical 
commissioning group training, British Heart Foundation 
training events and reading National Institute for Health 
and Care Excellence guidelines. This represents training 
with great variability, potential inadequacy (only reading 
material/online information/lack of practical experi-
ence) and some reliance on interested parties like manu-
facturers to deliver the training.
We found there was good correlation between BP 
training and medicine use reviews (MUR) or new medi-
cine services (NMS) (r=0.605 to 0.715), suggesting if 
pharmacists are trained on BP services, they are likely to 
have engaged in other professional training like MUR 
and NMS accreditation which is intended to encourage 
safe and appropriate use of medicines.45
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Table 5 Type of training received
Type of training
Response 
frequency
Informal chat with the senior pharmacist 33
Training provided by the monitor manufacturer 6
Read internal company standard operating 
procedures
41
Read Royal Pharmaceutical Society Guidelines 11
Completed Centre for Pharmacy Postgraduate 
Education training
13
Other 12
Visual or manual checks of monitor
Respondents self- reported in- situ checks that were 
conducted during each consultation. Forty (61%) respon-
dents performed some visual or manual checks to ensure 
they were achieving accurate results, 26 (39%) did not. 
These, variously, included a visual check of the integrity of 
the monitor, checks for properly affixed tubing, working 
batteries, appropriate and secure cuff positioning of 
Velcro, correct inflation and deflation without air leaks 
and of the display screen (no error codes). General clean-
liness and physical damage (eg, holes) was assessed, in 
addition to simply checking that the machine was turned 
on and actually providing BP and pulse readings. Four 
respondents would check their own (and colleagues’) BP 
to assess whether the monitor was working well.
Instructions to patients/customers
We also inquired about the instructions provided to 
patients prior to screening. Sixty- four positive answers 
were received indicating that most respondents would 
instruct their patients, with only one respondent saying 
they would give no instructions (one missing). Instruc-
tions, variously, included to remove restrictive clothing, 
be seated, relax, have both feet on the ground, legs apart 
and not crossed, rest their elbow on the table with wrist 
facing up and not to talk. Respondents also, variously, 
inquired if patients needed to empty their bladder or 
had recently consumed caffeine, smoked, felt stressed, 
made any blood donations and asked about past medical 
history, and drug history including any prescribed BP 
medication. One respondent said they would go through 
the consenting process (telling the patient what was 
involved and what to expect). Some patients were given a 
customer card with a copy of their readings.
We asked if there were any other considerations respon-
dents would make, and they responded in terms either 
of assessing the reliability of the BP readings generated, 
considering the most pragmatic way of conducting the 
tests or how best to communicate with patients. Forty- one 
comments were received. One respondent would 
consider patient age and weight as part of the assess-
ment. A few suggested the need for multiple readings, 
that they ‘might take an average of three readings’. Many 
would consider prescribed medicines currently taken by 
the patient. Respondents also would explain the reading 
and give relevant lifestyle and health promotion advice 
with respect to exercise, diet, smoking and alcohol or 
other beverages (eg, coffee, energy drink). One consid-
ered if the patient had a pacemaker fitted or potential 
pregnancy. One respondent would consider if patients 
had breast or underarm surgery. Respondents would also 
generally take into consideration the patient’s character, 
stress levels, demeanour, life and work and assess if white 
coat syndrome was present leading to unreliable readings. 
One respondent took into account ambient temperature, 
that is, heat. Some inquired why the patient is requesting 
a BP measurement.
We invited any other additional comments. Comments 
included that one respondent had ordered a large cuff 
and another was considering replacing or getting their 
monitor calibrated because of the survey. Some respon-
dents were proactive at measuring BP by facilitating well- 
being days.
The potential extension to the role of community phar-
macy was highlighted by one respondent who commented, 
‘Clients sometimes use us to record BP on their PMR (pharmacy 
patient medical records) & then take print out to GP to help record 
issues. When white coat syndrome, GPs will refer to us.’ This 
suggests current practice may include referring patients 
to GP for follow- on care. It also importantly hints at lower 
rates of white coat syndrome in pharmacy settings than in 
physician clinics and that GPs actively refer patients for 
screening in pharmacy settings for this reason.
Deprivation
Pharmacies in all deciles from most deprived to least 
deprived responded, with relatively even distribution per 
decile. Table 6 summarises our findings stratified by the 
most deprived deciles (a 1 of 10 subdivision) versus their 
more affluent counterparts.
Table 6 suggests higher frequency of BP screening by 
community pharmacy providers in the most deprived post-
codes, though this is not statistically significant reflecting 
small sample size. Service utilisation was approximately 
even. Respondents in less deprived areas were slightly 
more likely to have a validated monitor, though again this 
is not statistically significant. Calibration rates and length 
of time in service of monitors show limited relationship 
to deprivation of surrounding area. Granular decile infor-
mation is available (see online supplementary appendix 
B).
Provision of the service was linked to lower income 
rank (F=4.029, p=0.047) and lower employment rank 
(F=4.651, p=0.033).
DISCuSSIOn
Summary
Hypertension- related appointments make up almost 1 
in 10 of all GP consultations each year.46 With the work-
load of GPs thought to be nearing saturation point,47 
alternative models of hypertension management such 
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Table 6 Respondent Index of Multiple Deprivation decile distribution
Deciles (1=most 
deprived,
10=least deprived)
Number of 
respondents
BP service 
providers
Service utilisation 
(number of people 
screened)
Validated 
monitor 
status
Quality of service 
(calibration status)
Quality of service 
(purchase date)
Deprived deciles 1, 2 
and 3.
49 (45%) 33 (67%) 1–5 people screened 
by 12 respondents.
6–10 people screened 
by 12 respondents.
11–15 people 
screened by five 
respondents.
15+ people screened 
by three respondents.
18 (55%) Four calibrated 0–1 
year ago.
Two calibrated 1–2 
years ago.
Two calibrated 2–5 
years ago.
None calibrated 5–10 
years ago.
One calibrated 10+ 
years ago.
Four purchased 0–1 
year ago.
Eight purchased 1–2 
years ago.
Seven purchased 2–5 
years ago.
Two purchased 5–10 
years ago.
None purchased 10+ 
years ago.
Affluent deciles 4, 5, 
6, 7, 8, 9 and 10.
60 (55%) 33 (55%) 1–5 people screened 
by 13 respondents.
6–10 people screened 
by 10 respondents.
11–15 people 
screened by three 
respondents.
15+ people 
screened by seven 
respondents.
22 (67%) Three calibrated 0–1 
year ago.
Two calibrated 1–2 
years ago.
Four calibrated 2–5 
years ago.
One calibrated 5–10 
years ago.
None calibrated 10+ 
years ago.
Six purchased 0–1 year 
ago.
Six purchased 1–2 
years ago.
Five purchased 2–5 
years ago.
Four purchased 5–10 
years ago.
One purchased 10+ 
years ago.
Total 109 66   40     
as pharmacist- led care have the potential to alleviate 
this increasing burden on primary healthcare systems. 
Evidence from systematic reviews shows that such interven-
tions can significantly reduce blood pressure compared 
with usual GP care.25 48 To explore the potential of imple-
menting extended pharmacist roles in the management 
of hypertension in community settings, it is essential to 
describe current practice.
We found between 1 to 10 people were routinely 
screened monthly by each pharmacy. Annually, respon-
dents said they screened between 10 to 2000 people 
(where 2000 could be an outlier). These figures seem 
credible as they give annualised average figures of at 
least 10 to 12 people screened by each service provider 
(the higher annual figures may reflect pharmacies 
participating in national campaigns such as ‘Know Your 
Numbers’ (http://www. bloodpressureuk. org/ HealthPro-
fessionals/ KnowyourNumbersWeek) at other points in 
the year). This rate of screening conservatively detected 
one to two undiagnosed hypertensive patients monthly 
per service provider. If these estimates are scaled- up for 
England and annualised across the 11 619 pharmacies in 
England, assuming a 60% service provision rate, it would 
represent detection of an additional 83 657 to 167 314 
undiagnosed hypertensives, identifying 2% of the total 
undiagnosed hypertensive English population. In 7 years, 
in its current state, the service could help diagnose 1.185 
million people saving the NHS £120 million.9
Most monitors were automatic digital monitors, 
selected by head office or as a convenient model, but 
price and product guarantees may also play an influential 
role in monitor selection, rather than validation status. 
Lack of a range of cuff sizes per provider appears a major 
issue, as only 59% (39/66) stocked a medium cuff and 
41% (27/66) a large cuff, with only a minority reporting 
they stocked multiple cuff sizes.
Many monitors were old which may risk inaccuracy. 
Fifty- six percent of service providers replaced the moni-
tors at least every 2 years, but only 14% (9/63) every year 
or more frequently, and 30% did not replace at all. This 
may be because often calibration is guaranteed for up 
to 2 years from the date of purchase by manufacturers. 
However, previous studies recommend at least annual 
calibration with evidence suggesting declining perfor-
mance after 18 months.22
Calibration of devices was reported by 27% of service 
providers. Overall, this means 23% (15/66) of service 
providers neither replaced nor calibrated their devices.
While 92% of service providers received some training 
of variable quality, 8% reported not receiving any. While 
this is poor, it provides a benchmark for future training- 
quality enhancements.
Strengths and limitations
This study provides needed evidence on the quality of BP 
screening from community pharmacy. There are several 
novelties to our study. We have for the first time reported 
on prevalence of service provision (61%), level of service 
utilisation and validation and calibration status within 
community pharmacy practice in England. This is the 
most comprehensive service evaluation on BP monitoring 
service provision in pharmacies in the UK.
Though we have structured this study robustly, there is 
a risk of bias. Key limitations of our study are small sample 
size and low response rate. It is possible that our results 
may be biassed towards more provision than is actually 
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Table 7 Respondent bias assessment based on dispensing volumes
NHS dispensing monthly (March 2018) statistics
Number of prescription forms 
(nominal)
Number of prescription items 
(nominal)
Mean
  (England) Population 3564 (3564±0) 7132 (7132±0)
  Invited 3633 (3564+69) 7366 (7132+234)
  Respondent 3693 (3564+129) 7444 (7132+312)
  Non- respondent (excluding closures and abatements) 3666 (3564+102) 7444 (7132+312)
SD
  (England) Population 2692 (2692±0) 5167 (5167±0)
  Invited 2053 (2692–639) 4296 (5167–871)
  Respondent 2154 (2692–538) 4569 (5167–598)
  Non- respondent (excluding closures and abatements) 1999 (2692–693) 4171 (5167–996)
NHS, National Health Service.
available, if pharmacies providing the service were more 
likely to respond. However, we did specify we were inter-
ested in hearing from non- service providers, and respon-
dents in such pharmacies would have needed much less 
time to complete the survey.
Some missing information may make the findings unre-
liable. This is a potential limitation of our study and in 
the future, we may seek ethical permission to telephone 
pharmacies to confirm missing information. For some 
respondents, there is discrepancy between monthly and 
annual screening numbers, which is a potential limita-
tion of this study and could reflect erratic answers, but 
it highlights the need for more research beyond a survey 
methodology.
We acknowledge that respondents often represent 
multiple chain pharmacies that have uniform standard 
operating procedures (SOPs) in branches across the 
country. Theoretically, this could bias our results. However, 
SOPs are interpreted, adapted and implemented differ-
ently within each branch and so our research provides a 
more authentic representation of practice.
Potential bias was assessed by examining the total 
number of prescription forms and items dispensed 
across England (table 7). Respondents tended to be from 
slightly busier pharmacies than non- respondents, though 
by a small margin, making our findings relevant.
Our pharmacies were typical of those nationwide, 
including in terms of deprivation of surrounding catch-
ment area. There was a good spread in terms of typology 
of pharmacy and location (geographically; urban, 
suburban, rural). Therefore, our results are robust, cred-
ible and generalisable.
Comparison with existing literature: Pharmacists can 
provide BP screening service at much reduced cost to the 
NHS compared with GP services.49 Pharmacists are gener-
ally available without appointment, open for extended 
hours during unsociable hours and have been shown to 
provide greater care in areas of highest deprivation.27 
Our mapping provides tentative support for this positive 
care law.
There may be a lower incidence of white coat syndrome 
in community pharmacy,50 and we found evidence of 
GPs using pharmacies to screen for white coat hyperten-
sion. The potential role of pharmacies in hypertension 
management through BP testing (checking for white coat 
syndrome, monitoring the effectiveness of medication) 
is there, in addition to screening for new hypertension 
cases. Lower rates of white coat syndrome in these settings 
is supported in the Palmera study.50
Implications for clinical practice
Significant quality enhancements need to be imple-
mented. It is important to consider the patient popu-
lation this study may impact most. The ‘hard to reach’ 
groups of patients are typically less affluent and are also 
less likely to see their GP (or not have a GP), and have 
poor health literacy. There may be a greater likelihood 
of identifying new previously undetected cases of hyper-
tension in this group of the population. Community 
pharmacies are easily accessible and located in all areas, 
and have been shown to provide greater care in areas 
of highest deprivation which may be more conducive 
for the ‘hard to reach’ patient groups and could assist 
in reducing health inequalities nationally. Focusing 
attention on these people at the right time can avoid 
hospital costs and allow the patient to remain within the 
community.
Pharmacies deliver a valuable service of providing free 
BP checks to those who feel they cannot afford to buy 
monitors. In affluent areas, it may be that more people are 
self- monitoring with their own- bought home- monitors, 
and there is simply less demand on pharmacies.
Collectively, this provides a social and health economic 
argument for pharmacists to be involved in routine, NHS- 
commissioned, hypertension screening for the general 
population with needed quality enhancements.
Protected by copyright.
 o
n
 D
ecem
ber 12, 2019 at UNIVERSITY O
F BRIG
HTO
N.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-032342 on 11 December 2019. Downloaded from 
9Barrett R, Hodgkinson J. BMJ Open 2019;9:e032342. doi:10.1136/bmjopen-2019-032342
Open access
Our recommendations
Based on these results, we recommend in- service rede-
sign and delivery improvements, and suggest professional 
bodies and researchers work together to create clearer 
frameworks for front- line practitioners, creating appro-
priate incentives to facilitate this service redesign.
Specifically we recommend that pharmacies providing 
this service: (1) Use validated BP monitors, calibrated at 
1 yearly intervals; (2) Maintain audited records incorpo-
rating monitor details, service history and use frequency; 
(3) Stock at least three cuff sizes; (4) Train service staff 
to quality standards both in a theoretical- based and 
competency- based framework, which is accredited.
Further research needs to be conducted to demonstrate 
the sufficiency of these measures, which once achieved, 
could be a nationally commissioned service. Ongoing 
analysis of this work needs to consider local area depriva-
tion status with priority given to these service providers.
COnCluSIOn
The majority of pharmacies use validated BP monitors. 
In general, responding pharmacies were able to provide 
useful BP monitoring services to their patients, though 
quality enhancements need to be implemented. There 
was a lack of range of cuff sizes, variation in recruitment 
and calibration of monitors and apparent absence of any 
replacement or calibration in a minority of pharmacies, 
variation in training standards. Community pharmacists 
could play a leading role in BP screening in England.
Funders and policy setters should consider the value 
added to the NHS and other healthcare agencies of such 
screening by pharmacy providers both nationally and 
internationally. It has the potential to reduce complica-
tions of undiagnosed hypertension and the medicines 
burden that it creates.
Future research needs
A larger study is required to validate our findings. Future 
work should examine the impact of pharmacist- led BP 
screening on patients. At the very least, we need to study 
the patient population, their needs in their local context 
and which areas or groups represent most undiagnosed 
people. We encourage the international research commu-
nity to use our survey to report their findings.
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